To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
Already have an account?
Bruker and the University of Warwick Collaborates for Further Development of Extreme Performance Mass Spectrometry
Read time: 1 minute
Bruker Daltonics has announced the establishment of a long-term collaborative programme for developing both applications and fundamental instrument technology in the area of extreme resolution mass spectrometry.
Building on over 14 years of experience in high performance mass spectrometry at the Department of Chemistry at Warwick, the University’s recent acquisition of both the new Bruker solariX™ 12 Tesla FTMS system and the maXis™ UHR-TOF system again puts the department at the forefront of technology for high performance mass spectrometry.
At the core of the new instruments are improvements, up to an order of magnitude, in previous performance standards. These advances help address the challenging analyses including very complex mixtures in applications such as chemistry, medicinal discovery, protein interactions and petroleomics.
The collaboration is unusual in that it embraces not only topical applications innovation but also fundamental instrument development, the latter headed by Warwick Professor Peter O’Connor, who recently arrived from Boston University, and is one of the world’s most accomplished FTMS instrument development scientists.
“We are very excited to be able to benefit from Peter’s ideas, and have arranged a technical fast-track for his developments to appear in our FTMS products,” commented Dr. Michael Schubert, Executive Vice President for R&D at Bruker Daltonics.
Professor Peter Sadler, Head of Chemistry at the University, whose research interests focus on metals in biology and medicine, the design and mechanism of action of metallodrugs, especially the role of proteins in metal-induced signal transduction said: “In my field state-of-the-art analysis of metal speciation holds the key to major breakthroughs in understanding both how metal ions control natural biological processes, and how metal complexes can be designed as novel therapeutic agents. Moreover, this new Bruker mass spec equipment, and the associated collaboration, will allow our newly established EPSRC Warwick Centre for Analytical Science to compete strongly at the forefront of the field.”
Building on over 14 years of experience in high performance mass spectrometry at the Department of Chemistry at Warwick, the University’s recent acquisition of both the new Bruker solariX™ 12 Tesla FTMS system and the maXis™ UHR-TOF system again puts the department at the forefront of technology for high performance mass spectrometry.
At the core of the new instruments are improvements, up to an order of magnitude, in previous performance standards. These advances help address the challenging analyses including very complex mixtures in applications such as chemistry, medicinal discovery, protein interactions and petroleomics.
The collaboration is unusual in that it embraces not only topical applications innovation but also fundamental instrument development, the latter headed by Warwick Professor Peter O’Connor, who recently arrived from Boston University, and is one of the world’s most accomplished FTMS instrument development scientists.
“We are very excited to be able to benefit from Peter’s ideas, and have arranged a technical fast-track for his developments to appear in our FTMS products,” commented Dr. Michael Schubert, Executive Vice President for R&D at Bruker Daltonics.
Professor Peter Sadler, Head of Chemistry at the University, whose research interests focus on metals in biology and medicine, the design and mechanism of action of metallodrugs, especially the role of proteins in metal-induced signal transduction said: “In my field state-of-the-art analysis of metal speciation holds the key to major breakthroughs in understanding both how metal ions control natural biological processes, and how metal complexes can be designed as novel therapeutic agents. Moreover, this new Bruker mass spec equipment, and the associated collaboration, will allow our newly established EPSRC Warwick Centre for Analytical Science to compete strongly at the forefront of the field.”
